Generic Medicine Info
May be taken with or without food.
Severe bradyarrhythmia secondary to 2nd- or 3rd-degree AV block or sick sinus syndrome. Epidural administration: Inj site infection, concomitant anticoagulant therapy, bleeding diathesis, administration above the C4 dermatome.
Special Precautions
Patient with CV disease (e.g. severe coronary insufficiency, recent MI, conduction disturbances including sinus node dysfunction), haemodynamic instability; cerebrovascular disease; occlusive peripheral vascular disorders (e.g. Raynaud's disease), pre-existing or risk factors for bradycardia; pre-existing or history of depression. Avoid abrupt withdrawal. Renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure (standing and sitting/supine positions), heart rate and mental status. Epidural: Monitor for catheter-related infection (e.g. meningitis or epidural abscess).
Adverse Reactions
Significant: Hypotension, bradycardia, CNS depression, respiratory depression, xerostomia, skin rash (transdermal). Cardiac disorders: Sinus bradycardia. Gastrointestinal disorders: Constipation, nausea, salivary gland pain, vomiting. General disorders and administration site conditions: Fatigue, malaise. Nervous system disorders: Drowsiness, dizziness, sedation, headache, paraesthesia. Psychiatric disorders: Sleep disorder, depression, hallucination, delusional perception, nightmare. Reproductive system and breast disorders: Erectile dysfunction. Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria. Vascular disorders: Orthostatic hypotension (1st dose), Raynaud's phenomenon.
Drug Interactions
Increased hypotensive effect with narcotic analgesic and other antihypertensive agents (e.g. diuretics, β-blockers, vasodilators, Ca antagonists, ACE inhibitors). May potentiate CNS depressant effect of barbiturates or other sedating drugs. Reduced antihypertensive effect and induced orthostatic hypotension with TCAs or neuroleptics with α-receptor blocking properties. Diminished antihypertensive effect with mirtazapine. May potentiate AV-blocking effect of cardiac glycosides. May increase arrhythmogenic potential (e.g. QT prolongation, ventricular fibrillation) of high doses of IV haloperidol.
CIMS Class
Other Antihypertensives
ATC Classification
C02AC01 - clonidine ; Belongs to the class of imidazoline receptor agonists, centrally-acting antiadrenergic agents. Used in the treatment of hypertension.
N02CX02 - clonidine ; Belongs to the class of other antimigraine preparations.
S01EA04 - clonidine ; Belongs to the class of sympathomimetics used in the treatment of glaucoma.
Disclaimer: This information is independently developed by CIMS based on clonidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in